1. Home
  2. BROS vs DVA Comparison

BROS vs DVA Comparison

Compare BROS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dutch Bros Inc.

BROS

Dutch Bros Inc.

HOLD

Current Price

$62.10

Market Cap

8.1B

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$104.88

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BROS
DVA
Founded
1992
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Misc Health and Biotechnology Services
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
8.2B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
BROS
DVA
Price
$62.10
$104.88
Analyst Decision
Strong Buy
Hold
Analyst Count
18
4
Target Price
$76.72
$145.00
AVG Volume (30 Days)
2.9M
799.0K
Earning Date
02-11-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
56.73
5.63
EPS
0.51
9.76
Revenue
$1,537,335,000.00
$13,317,965,000.00
Revenue This Year
$28.88
$6.50
Revenue Next Year
$25.56
$2.97
P/E Ratio
$122.84
$10.73
Revenue Growth
28.93
5.14
52 Week Low
$47.16
$101.00
52 Week High
$86.88
$179.60

Technical Indicators

Market Signals
Indicator
BROS
DVA
Relative Strength Index (RSI) 51.20 29.58
Support Level $59.50 $101.00
Resistance Level $63.29 $106.38
Average True Range (ATR) 2.33 3.05
MACD -0.35 -0.77
Stochastic Oscillator 50.32 26.82

Price Performance

Historical Comparison
BROS
DVA

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: